Attached files
| file | filename |
|---|---|
| EX-99.1 - MusclePharm Corp | v206361_ex99-1.htm |
SECURITIES
AND EXCHANGE COMMISSION
Washington D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(D) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date of
Report (Date of earliest event reported): December 21,
2010
MusclePharm
Corporation
(Exact
Name of Registrant as Specified in its Charter)
|
Nevada
|
000-53166
|
77-0664193
|
|
(State or Other Jurisdiction
of incorporation)
|
(Commission File No.)
|
(I.R.S. Employer
Identification Number)
|
4721
Ironton Street
Denver,
Colorado 90839
(Address
of Principal Executive Offices)
Registrant’s
telephone number, including area code: (800) 210-7369
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item 5.02 Departure of Directors
and Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.
Resignation
of Director
Item
9.01 Financial Statements and Exhibits.
|
Exhibit
No.
|
Description
|
|
99.1
|
Resignation
Letter of Michael Shawn Wingate, dated as of December 21,
2010.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
MUSCLEPHARM
CORPORATION
|
|||
|
Date:
December 22, 2010
|
By:
|
/s/ Brad
Pyatt
|
|
|
Brad
Pyatt
|
|||
|
Chief
Executive Officer
|